(Q40582093)

21 September 2017

title

Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts (English)

1 reference

21 September 2017

Øystein Bruserud

1

1 reference

21 September 2017

Nils Glenjen

series ordinal

2

1 reference

21 September 2017

Anita Ryningen

series ordinal

3

1 reference

21 September 2017

publication date

1 July 2003

1 reference

European Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

volume

71

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

9-17

1 reference

21 September 2017

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Regulation of endothelial cell survival and apoptosis during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Local endostatin treatment of gliomas administered by microencapsulated producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

New strategies for the treatment of acute myelogenous leukemia: differentiation induction--present use and future possibilities

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00080.X

7 January 2021

10.1034/J.1600-0609.2003.00080.X

Identifiers

DOI

1 reference

21 September 2017

1 reference